|
|
|
|
The Burden of CVD in Asia
|
|
|
|
The Burden of CVD in Asia
|
|
|
|
Age-Standardized Stroke and CHD
|
|
|
|
Projected Stroke and CHD Increase to 2030 in China
|
|
|
|
|
Discovery of statins
|
|
|
|
Clear Cardiovascular Benefits
|
|
|
|
Second CTT cycle:
|
|
|
|
Proportional effects on MAJOR VASCULAR EVENTS
|
|
|
|
Absolute effect of statin therapy
|
|
|
|
ASAP: Atorvastatin Reduced CRP
|
|
|
|
Anglo-Scandinavian Cardiac Outcomes Trial
|
|
|
|
ASCOT-LLA
|
|
|
|
PROVE IT: Study Design
|
|
|
|
PROVE IT:
|
|
|
|
|
|
|
Statin Safety in Perspective
|
|
|
|
Safety of Atorvastatin 80 mg in Clinical Trials
|
|
|
|
Is Current LDL Reduction Enough?
|
|
|
|
The Future of Best Practice
|
|
|
|
REVERSAL
|
|
|
|
REVERSAL
|
|
|
|
REVERSAL
|
|
|
|
Estimated GFR and Clinical Outcomes
|
|
|
|
Preventing the clinical manifestations (PPTX 2.7MB)
Share this page with your colleagues and friends: